Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Liver Injury in COVID-19: A Direct Hit or Collateral Damage?

Author(s): Balasubramaniyan Vairappan*, Gavin Wright, Douglas Corrigal and Ravikumar TS

Volume 22, Issue 1, 2022

Published on: 13 September, 2021

Article ID: e130921196417 Pages: 13

DOI: 10.2174/1871526521666210913110500

Price: $65

Abstract

SARS-CoV-2 is a novel coronavirus that has been identified, in December 2019, in Wuhan, China, and since it has become a worldwide pandemic, it has imposed far-reaching impacts on global human health and socio-economic activity. Worldwide, over 4 million Covid-19 related deaths were reported until September 2021. Recently published case studies have reported that Covid-19 patients develop different degrees of liver dysfunction. Inevitably, in hospitalized Covid-19 patients who develop acute liver derangement, there are a plethora of potential pathogenic causes such as direct-viral, immune-driven, and drug-induced and/or ischaemic liver injury. Patients with advanced chronic liver diseases (e.g., cirrhosis) and/or autoimmune liver disease have a poor immune function and associated poorer outcomes compared to other critically ill cohorts. However, largely any immediate liver derangement tends to be relatively mild, and as such, any de novo liver injury may not be a significant feature of Covid-19. There is an immediate necessity, therefore, to better understand the liver-specific pathophysiology of COVID-19. This review focuses on the up-to-date information regarding Covid-19 and associated indices for liver dysfunction, possible mechanisms, and potential drug targeted therapies in Covid-19 patients with and without liver dysfunction. PubMed database was used to perform an extensive literature search using the keywords liver and SARS-CoV-2, liver and Covid-19, Covid 19 and treatment, etc.

Keywords: ACE 2, cytokine storm, liver disease, SARS-CoV-2, inflammation, liver function marker.

Graphical Abstract

[1]
Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020; 382(10): 929-36.
[http://dx.doi.org/10.1056/NEJMoa2001191] [PMID: 32004427]
[2]
Bicheng Zhang XZ, Qiu Y, Feng F, et al. Clinical characteristics of 82 death cases with COVID-19. medRxiv 2020; 1-30.
[3]
Xu J, Zhao S, Teng T, et al. Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV-2 and SARS-CoV. Viruses 2020; 12(2)E244
[http://dx.doi.org/10.3390/v12020244] [PMID: 32098422]
[4]
Zhou H, Chen X, Hu T, et al. .A novel bat coronavirus closely related to SARS-CoV-2 contains natural insertions at the S1/S2 cleavage site of the spike protein. Curr Biol 2020; 30(11): 2196-03. ,e3
[http://dx.doi.org/10.1016/j.cub.2020.05.023]
[5]
Peeri NC, Shrestha N, Rahman MS, et al. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? Int J Epidemiol 2020; 49(3): 717-26.
[http://dx.doi.org/10.1093/ije/dyaa033] [PMID: 32086938]
[6]
Yu P, Zhu J, Zhang Z, Han Y. A familial cluster of infection associated with the 2019 novel coronavirus indicating possible person-to-person transmission during the incubation period. J Infect Dis 2020; 221(11): 1757-61.
[http://dx.doi.org/10.1093/infdis/jiaa077] [PMID: 32067043]
[7]
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
[8]
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323(11): 1061-9.
[9]
Cai Q, Huang D, Yu H, et al. COVID-19: Abnormal liver function tests. J Hepatol 2020; 73(3): 566-74.
[http://dx.doi.org/10.1016/j.jhep.2020.04.006] [PMID: 32298767]
[10]
Gu J, Han B, Wang J. COVID-19: Gastrointestinal manifestations and potential fecal-oral transmission. Gastroenterology 2020; 158(6): 1518-9.
[http://dx.doi.org/10.1053/j.gastro.2020.02.054] [PMID: 32142785]
[11]
Mantovani A, Beatrice G, Dalbeni A. Coronavirus disease 2019 and prevalence of chronic liver disease: A meta-analysis. Liver Int 2020; 40(6): 1316-20.
[http://dx.doi.org/10.1111/liv.14465] [PMID: 32329563]
[12]
Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. ]Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology 2020; 158(6)1831-1833 e3..
[13]
WHO. COVID 19 public health emergency of international concern (PHEIC) global research and innovation forum: towards a research roadmap. Glopid-R 2020.
[14]
Aldridge RWLD, Katikireddi SV, Mathur R, et al. Black, Asian and minority ethnic groups in England are at increased risk of death from COVID-19: indirect standardisation of NHS mortality data. Wellcome Open Res 2020; 5: 88.
[15]
Bangash MN, Patel J, Parekh D. COVID-19 and the liver: little cause for concern. Lancet Gastroenterol Hepatol 2020; 5(6): 529-30.
[http://dx.doi.org/10.1016/S2468-1253(20)30084-4] [PMID: 32203680]
[16]
Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol 2020; 5(5): 428-30.
[http://dx.doi.org/10.1016/S2468-1253(20)30057-1] [PMID: 32145190]
[17]
Hashemi N, Viveiros K, Redd WD, et al. Impact of chronic liver disease on outcomes of hospitalized patients with COVID-19: A multicentre United States experience. Liver Int 2020; 40(10): 2515-21.
[http://dx.doi.org/10.1111/liv.14583] [PMID: 32585065]
[18]
Zhou YJ, Zheng KI, Wang XB, et al. Metabolic-associated fatty liver disease is associated with severity of COVID-19. Liver Int 2020; 40(9): 2160-3.
[http://dx.doi.org/10.1111/liv.14575] [PMID: 32573883]
[19]
Iavarone M, D’Ambrosio R, Soria A, et al. High rates of 30-day mortality in patients with cirrhosis and COVID-19. J Hepatol 2020.
[20]
Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382(18): 1708-20.
[http://dx.doi.org/10.1056/NEJMoa2002032] [PMID: 32109013]
[21]
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223): 507-13.
[http://dx.doi.org/10.1016/S0140-6736(20)30211-7] [PMID: 32007143]
[22]
Zhang Y, Zheng L, Liu L, Zhao M, Xiao J, Zhao Q. Liver impairment in COVID-19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city, China. Liver Int 2020; 40(9): 2095-103.
[23]
Ying Huang RY, Xu Y, Gong P. Clinical characteristics of 36 nonsurvivors with COVID-19 in Wuhan, China. medRxiv 2020; 1-21.
[http://dx.doi.org/10.1101/2020.02.27.20029009]
[24]
Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver Int 2020; 40(5): 998-1004.
[http://dx.doi.org/10.1111/liv.14435] [PMID: 32170806]
[25]
Lin Fu JF, Xiang H-X, Xiang Y, et al. .Influence factors of death risk among COVID-19 patients in Wuhan, China: a hospital-based case-cohort study. medRxiv 2020; 1-20.
[26]
Chen LY, Chu HK, Bai T, et al. Liver damage at admission is an independent prognostic factor for COVID-19. J Dig Dis 2020; 21(9): 512-8.
[http://dx.doi.org/10.1111/1751-2980.12925] [PMID: 32713118]
[27]
Sun J, Aghemo A, Forner A, Valenti L. COVID-19 and liver disease. Liver Int 2020; 40(6): 1278-81.
[http://dx.doi.org/10.1111/liv.14470] [PMID: 32251539]
[28]
Feng G, Zheng KI, Yan QQ, et al. COVID-19 and liver dysfunction: Current insights and emergent therapeutic strategies. J Clin Transl Hepatol 2020; 8(1): 18-24.
[http://dx.doi.org/10.14218/JCTH.2020.00018] [PMID: 32274342]
[29]
Lleo A, Invernizzi P, Lohse AW, Aghemo A, Carbone M. Management of patients with autoimmune liver disease during COVID-19 pandemic. J Hepatol 2020; 73(2): 453-5.
[http://dx.doi.org/10.1016/j.jhep.2020.04.002] [PMID: 32283134]
[30]
Di Giorgio A, D’Antiga L. Acute liver failure in children: Is it time to revise the diagnostic criteria? Liver Transpl 2020; 26(2): 184-6.
[http://dx.doi.org/10.1002/lt.25693] [PMID: 31778017]
[31]
Huang J, Lin H, Wu Y, et al. COVID-19 in posttransplant patients-report of 2 cases. Am J Transplant 2020; 20(7): 1879-81.
[http://dx.doi.org/10.1111/ajt.15896] [PMID: 32243697]
[32]
Tapper EB, Asrani SK. The COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care. J Hepatol 2020; 73(2): 441-5.
[http://dx.doi.org/10.1016/j.jhep.2020.04.005] [PMID: 32298769]
[33]
Albini A, Di Guardo G, Noonan DM, Lombardo M. The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies. Intern Emerg Med 2020; 15(5): 759-66.
[http://dx.doi.org/10.1007/s11739-020-02364-6] [PMID: 32430651]
[34]
Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395(10234): 1417-8.
[http://dx.doi.org/10.1016/S0140-6736(20)30937-5] [PMID: 32325026]
[35]
Xiaoqiang Chai LH, Zhang Yan , Han Weiyu, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019- ncov infection. bio Rxiv 2020.
[36]
Chau TN, Lee KC, Yao H, et al. SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases. Hepatology 2004; 39(2): 302-10.
[http://dx.doi.org/10.1002/hep.20111] [PMID: 14767982]
[37]
Alsaad KO, Hajeer AH, Al Balwi M, et al. Histopathology of Middle East respiratory syndrome coronovirus (MERS-CoV) infection - clinicopathological and ultrastructural study. Histopathology 2018; 72(3): 516-24.
[http://dx.doi.org/10.1111/his.13379] [PMID: 28858401]
[38]
Zhao B, Ni C, Gao R, et al. Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids. Protein Cell 2020; 11(10): 771-5.
[http://dx.doi.org/10.1007/s13238-020-00718-6] [PMID: 32303993]
[39]
Vairappan B. Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stress. World J Hepatol 2015; 7(3): 443-59.
[http://dx.doi.org/10.4254/wjh.v7.i3.443] [PMID: 25848469]
[40]
Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020; 8(4): 420-2.
[http://dx.doi.org/10.1016/S2213-2600(20)30076-X] [PMID: 32085846]
[41]
Wang Y, Liu S, Liu H, et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol 2020; 73(4): 807-16.
[42]
Chien JY, Hsueh PR, Cheng WC, Yu CJ, Yang PC. Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome. Respirology 2006; 11(6): 715-22.
[http://dx.doi.org/10.1111/j.1440-1843.2006.00942.x] [PMID: 17052299]
[43]
Chu H, Zhou J, Wong BH, et al. Middle East respiratory syndrome coronavirus efficiently infects human primary T lymphocytes and activates the extrinsic and intrinsic apoptosis pathways. J Infect Dis 2016; 213(6): 904-14.
[http://dx.doi.org/10.1093/infdis/jiv380] [PMID: 26203058]
[44]
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229): 1054-62.
[http://dx.doi.org/10.1016/S0140-6736(20)30566-3] [PMID: 32171076]
[45]
Jingyuan Liu YL, Xiang P, Pu L, et al. Neutrophil-to-lymphocyte ratio predicts severe illness patients with 2019 novel coronavirus in the early stage. medRxiv 2020.
[46]
Heurich A, Hofmann-Winkler H, Gierer S, Liepold T, Jahn O, Pöhlmann S. TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. J Virol 2014; 88(2): 1293-307.
[http://dx.doi.org/10.1128/JVI.02202-13] [PMID: 24227843]
[47]
Cals JW, Schot MJ, de Jong SA, Dinant GJ, Hopstaken RM. Point-of-care C-reactive protein testing and antibiotic prescribing for respiratory tract infections: a randomized controlled trial. Ann Fam Med 2010; 8(2): 124-33.
[http://dx.doi.org/10.1370/afm.1090] [PMID: 20212299]
[48]
Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020; 75(7): 1730-41.
[49]
Adams DH, Hubscher SG. Systemic viral infections and collateral damage in the liver. Am J Pathol 2006; 168(4): 1057-9.
[http://dx.doi.org/10.2353/ajpath.2006.051296] [PMID: 16565481]
[50]
Heymann F, Tacke F. Immunology in the liver-from homeostasis to disease. Nat Rev Gastroenterol Hepatol 2016; 13(2): 88-110.
[http://dx.doi.org/10.1038/nrgastro.2015.200] [PMID: 26758786]
[51]
Wu J, Song S, Cao HC, Li LJ. Liver diseases in COVID-19: Etiology, treatment and prognosis. World J Gastroenterol 2020; 26(19): 2286-93.
[http://dx.doi.org/10.3748/wjg.v26.i19.2286] [PMID: 32476793]
[52]
Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations. (*) Annu Rev Immunol 2010; 28: 445-89.
[http://dx.doi.org/10.1146/annurev-immunol-030409-101212] [PMID: 20192806]
[53]
McBride JA, Striker R. Imbalance in the game of T cells: What can the CD4/CD8 T-cell ratio tell us about HIV and health? PLoS Pathog 2017; 13(11)e1006624
[http://dx.doi.org/10.1371/journal.ppat.1006624] [PMID: 29095912]
[54]
Ganji A, Farahani I, Khansarinejad B, Ghazavi A, Mosayebi G. Increased expression of CD8 marker on T-cells in COVID-19 patients. Blood Cells Mol Dis 2020; 83102437
[http://dx.doi.org/10.1016/j.bcmd.2020.102437] [PMID: 32325421]
[55]
Kang CK, Han GC, Kim M, et al. Aberrant hyperactivation of cytotoxic T-cell as a potential determinant of COVID-19 severity. Int J Infect Dis 2020; 97: 313-21.
[http://dx.doi.org/10.1016/j.ijid.2020.05.106] [PMID: 32492530]
[56]
Ulrich H, Pillat MM. CD147 as a target for covid-19 treatment: Suggested effects of azithromycin and stem cell engagement. Stem Cell Rev Rep 2020; 16(3): 434-40.
[http://dx.doi.org/10.1007/s12015-020-09976-7] [PMID: 32307653]
[57]
Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with covid-19 disease and unexposed individuals. Cell 2020; 181(7): 1489-1501.e15.
[http://dx.doi.org/10.1016/j.cell.2020.05.015] [PMID: 32473127]
[58]
Ji D, Qin E, Xu J, et al. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. J Hepatol 2020; 73(2): 451-3.
[http://dx.doi.org/10.1016/j.jhep.2020.03.044] [PMID: 32278005]
[59]
Rawat K, Kumari P, Saha L. COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies. Eur J Pharmacol 2021; 892173751
[http://dx.doi.org/10.1016/j.ejphar.2020.173751] [PMID: 33245898]
[60]
Kaur SP, Gupta V. COVID-19 vaccine: A comprehensive status report. Virus Res 2020; 288198114
[http://dx.doi.org/10.1016/j.virusres.2020.198114] [PMID: 32800805]
[61]
Turner AJ, Tipnis SR, Guy JL, Rice G, Hooper NM. ACEH/ACE2 is a novel mammalian metallocarboxypeptidase and a homologue of angiotensin-converting enzyme insensitive to ACE inhibitors. Can J Physiol Pharmacol 2002; 80(4): 346-53.
[http://dx.doi.org/10.1139/y02-021] [PMID: 12025971]
[62]
Amawi H, Abu Deiab GI. A Aljabali AA, Dua K, Tambuwala MM. COVID-19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics. Ther Deliv 2020; 11(4): 245-68.
[http://dx.doi.org/10.4155/tde-2020-0035] [PMID: 32397911]
[63]
Agarwal B, Wright G, Gatt A, et al. Evaluation of coagulation abnormalities in acute liver failure. J Hepatol 2012; 57(4): 780-6.
[http://dx.doi.org/10.1016/j.jhep.2012.06.020] [PMID: 22735303]
[64]
Stephanie A. Kujawski KKW, Jennifer P. Collins, Lauren Epstein, et al. First 12 patients with coronavirus disease 2019 (COVID-19) in the United States. medRxiv 2020.
[65]
Ye G, Pan Z, Pan Y, et al. Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation. J Infect 2020; 80(5): e14-7.
[http://dx.doi.org/10.1016/j.jinf.2020.03.001] [PMID: 32171867]
[66]
Deng Y, Liu W, Liu K, et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study. Chin Med J (Engl) 2020; 133(11): 1261-7.
[http://dx.doi.org/10.1097/CM9.0000000000000824]
[67]
Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020; 8(5): 475-81.
[http://dx.doi.org/10.1016/S2213-2600(20)30079-5] [PMID: 32105632]
[68]
Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis 2020; 20(4): 425-34.
[http://dx.doi.org/10.1016/S1473-3099(20)30086-4] [PMID: 32105637]
[69]
Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA 2020; 117(20): 10970-5.
[http://dx.doi.org/10.1073/pnas.2005615117] [PMID: 32350134]
[70]
Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020; 395(10236): 1569-78.
[http://dx.doi.org/10.1016/S0140-6736(20)31022-9] [PMID: 32423584]
[71]
Cao W. .Clinical features and laboratory inspection of novel coronavirus pneumonia (COVID-19) in Xiangyang, Hubei. medRxiv 2020.
[http://dx.doi.org/10.1101/2020.02.23.20026963]
[72]
Ferner RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19. BMJ 2020; 369: m1432.
[http://dx.doi.org/10.1136/bmj.m1432] [PMID: 32269046]
[73]
Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020; 56(1)105949
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105949] [PMID: 32205204]
[74]
Hammami MB, Garibaldi B, Shah P, et al. Clinical course of COVID-19 in a liver transplant recipient on hemodialysis and response to tocilizumab therapy: A case report. Am J Transplant 2020; 20(8): 2254-9.
[http://dx.doi.org/10.1111/ajt.15985] [PMID: 32359210]
[75]
Molina JM, Delaugerre C, Le Goff J, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect 2020; 50(4): 384.
[http://dx.doi.org/10.1016/j.medmal.2020.03.006] [PMID: 32240719]
[76]
Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19. N Engl J Med 2020; 382(19): 1787-99.
[http://dx.doi.org/10.1056/NEJMoa2001282] [PMID: 32187464]
[77]
Fan Z, Chen L, Li J, et al. Clinical features of covid-19-related liver functional abnormality. Clin Gastroenterol Hepatol 2020; 18(7): 1561-6.
[http://dx.doi.org/10.1016/j.cgh.2020.04.002] [PMID: 32283325]
[78]
Zhu Z, Lu Z, Xu T, et al. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J Infect 2020; 81(1): e21-3.
[http://dx.doi.org/10.1016/j.jinf.2020.03.060] [PMID: 32283143]
[79]
Fu B, Xu X, Wei H. Why tocilizumab could be an effective treatment for severe COVID-19? J Transl Med 2020; 18(1): 164.
[http://dx.doi.org/10.1186/s12967-020-02339-3] [PMID: 32290839]
[80]
Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol 2020; 92(7): 814-8.
[http://dx.doi.org/10.1002/jmv.25801] [PMID: 32253759]
[81]
Elfiky AA. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci 2020; 253117592
[http://dx.doi.org/10.1016/j.lfs.2020.117592] [PMID: 32222463]
[82]
Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment Available from:. https://clinicaltrials.gov/ct2/show/NCT04276688
[83]
Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 Available from:. https://clinicaltrials.gov/ct2/show/NCT04315298
[84]
Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure (TOCIVID) Available from:. https://clinicaltrials.gov/ct2/show/NCT04322773
[85]
Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID) (SARCOVID) Available from:. https://clinicaltrials.gov/ct2/show/NCT04357808
[86]
Clinical Trial of Sarilumab in Adults With COVID-19 (SARICOR). Available from:. https://clinicaltrials.gov/ct2/show/NCT04357860
[87]
Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019 Available from:. https://clinicaltrials.gov/ct2/show/NCT04310228
[88]
Corona Virus Disease; 2019.Patients Whose Nucleic Acids Changed From Negative to Positive Available from:. https://clinicaltrials.gov/ct2/show/NCT04333589
[89]
Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19. Available from:. https://clinicaltrials.gov/ct2/show/NCT04358549
[90]
Khambholja K, Asudani D. Potential repurposing of Favipiravir in COVID-19 outbreak based on current evidence. Travel Med Infect Dis 2020; 35101710
[http://dx.doi.org/10.1016/j.tmaid.2020.101710] [PMID: 32360327]
[91]
McKee DL, Sternberg A, Stange U, Laufer S, Naujokat C. Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacol Res 2020; 157104859
[http://dx.doi.org/10.1016/j.phrs.2020.104859] [PMID: 32360480]
[92]
Grein J, Ohmagari N, Shin D, et al. Compassionate use of Remdesivir for patients with severe covid-19. N Engl J Med 2020; 382(24): 2327-36.
[http://dx.doi.org/10.1056/NEJMoa2007016] [PMID: 32275812]
[93]
Chang Chen YZ, Huang J, Yin P, et al. Favipiravir versus arbidol for covid-19: A randomized clinical trial. medRxiv 2020.
[http://dx.doi.org/10.1101/2020.03.17.20037432]
[94]
Deng L, Li C, Zeng Q, et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. J Infect 2020; 81(1): e1-5.
[http://dx.doi.org/10.1016/j.jinf.2020.03.002] [PMID: 32171872]
[95]
A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia. Available from:. https://clinicaltrials.gov/ct2/show/NCT04255017
[96]
Randomized A. Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia. Available from: https://clinicaltrials.gov/ct2/show/NCT04261270
[97]
] Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection Available from:. https://clinicaltrials.gov/ct2/show/NCT04261907
[98]
Coagulopathy of COVID-19:. A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard CareAvailable from: https://clinicaltrials.gov/ct2/show/NCT04362085
[99]
Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC) (ATTACC). Available from:. https://clinicaltrials. gov/ct2/show/NCT04372589
[100]
Impact of an Intensified Thromboprofylaxis Protocol in COVID-19. Available from:. https://clinicaltrials.gov/ct2/show/NCT04394000
[101]
Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet 2020; 395(10225): 683-4.
[http://dx.doi.org/10.1016/S0140-6736(20)30361-5] [PMID: 32122468]
[102]
Yin Wang WJ, He Q, Wang C, et al. Early, low-dose and shortterm application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China. medRxiv 2020.
[103]
Wu R, Wang L, Kuo HD, et al. An update on current therapeutic drugs treating covid-19. Curr Pharmacol Rep 2020; 1-15.
[http://dx.doi.org/10.1007/s40495-020-00216-7] [PMID: 32395418]
[104]
Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19 (NoCovid)Available from:. https://clinicaltrials.gov/ct2/show/NCT04305457
[105]
Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED (NO COV-ED) Available from:. https://clinicaltrials.gov/ct2/show/NCT04338828
[106]
Inhaled Nitric Oxide for Preventing Progression in COVID-19 (NO-COVID-19). Available from:. https://clinicaltrials.gov/ct2/show/NCT04388683
[107]
Sirolimus in COVID-19 Phase 1 (SirCO-1)Available from:. https://clinicaltrials.gov/ct2/show/NCT04371640
[108]
Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes. Available from:. https://clinicaltrials.gov/ct2/show/NCT04409327
[109]
Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia (SCOPE). Available from:. https://ClinicalTrials.gov/show/NCT04341675
[110]
An Observational Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications (SISCO). Available from: https://clinicaltrials.gov/ct2/show/NCT04322188
[111]
Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia. Available from: https://clinicaltrials.gov/ct2/show/NCT04329650
[112]
Cheng RZ. Can early and high intravenous dose of vitamin C prevent and treat coronavirus disease 2019 (COVID-19)? Med Drug Discov 2020; 5100028
[113]
] Use of Ascorbic Acid in Patients With COVID 19. Available from: https://clinicaltrials.gov/ct2/show/NCT04323514
[114]
Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation (AVoCaDO). Available from: https://clinicaltrials.gov/ct2/show/NCT04357782
[115]
Colchicine in COVID-19: a Pilot Study (COLVID-19). Available from: https://clinicaltrials.gov/ct2/show/NCT04375202? term= Colchicine&cond=Covid-19&draw=2&rank=2

Rights & Permissions Print Cite
Article Metrics
58
1
© 2024 Bentham Science Publishers | Privacy Policy